X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bria-IMT (SV-BR-1-GM) is a genetically engineered human breast cancer cell line with features of immune cells. It is being evaluated in phase 3 clinical trials in combination with Zynyz (retifanlimab) for the treatment of advanced metastatic breast cancer.
Lead Product(s): SV-BR-1-GM,Retifanlimab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Bria-IMT
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
Bria-Pros+ is a novel off-the-shelf personalized immunotherapy. It is being evaluated in preclinical studies for the treatment of patients with prostate cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Bria-Pros+
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
Bria-IMT (SV-BR-1-GM) is an off-the-shelf targeted cellular immunotherapy. It is being evaluated in phase 3 clinical trials in combination with Zynyz (retifanlimab-dlwr) for the treatment of Metastatic breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Retifanlimab
Therapeutic Area: Oncology Product Name: Bria-IMT
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
The partnership aims to evaluate the Bria-IMT (SV-BR-1-GM), a cell based patented immunotherapy, combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.
Lead Product(s): SV-BR-1-GM,Retifanlimab
Therapeutic Area: Oncology Product Name: Bria-IMT
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: NYCBS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 04, 2023
Details:
Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy having both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.
Lead Product(s): SV-BR-1-GM,Undisclosed
Therapeutic Area: Oncology Product Name: Bria-IMT
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy having both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.
Lead Product(s): SV-BR-1-GM,Retifanlimab
Therapeutic Area: Oncology Product Name: Bria-IMT
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2023
Details:
Through the spin-off, certain pipeline assets of BriaCell, including Bria-TILsRx and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer were spun-out to BriaPro.
Lead Product(s): Bria-TILsRx
Therapeutic Area: Oncology Product Name: Bria-TILsRx
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: BriaPro Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger August 31, 2023
Details:
The Company intends to use the funds for the development of Bria-OTS™, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.
Lead Product(s): Bria-OTS
Therapeutic Area: Oncology Product Name: Bria-OTS
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 16, 2023
Details:
Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy having both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.
Lead Product(s): SV-BR-1-GM,Retifanlimab
Therapeutic Area: Oncology Product Name: Bria-IMT
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
The financing will be used in BriaCell’s upcoming pivotal study including SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line, in advanced metastatic breast cancer.
Lead Product(s): SV-BR-1-GM,Cyclophosphamide,Interferon Inoculation
Therapeutic Area: Oncology Product Name: SV-BR-1-GM
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Prevail Partners
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
